CASGEVY is the first, and only, gene editing therapy approved for the treatment of transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD) in Europe -- Italy has the largest ...

Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.

Vertex Pharmaceuticals Incorporated just reported a robust Q2 with earnings per share of $4.52, surpassing estimates and ...

NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

Vertex Pharmaceuticals Incorporated made headlines with a notable investment by Alaethes Wealth LLC, which scooped up 3,051 ...

Okenla Michael Ilesanmi, known as Vertex Stylist, is a Nigerian fashion stylist, designer, and founder of the contemporary fashion brand Vertex Garb. And for his bold, authentic, and culturally ...

Demi-fine Fashion Private Limited (Palmonas) has raised ₹55 crore [$6.3 million] in Series A Funding Round led by Vertex ...

Their research led to the development of a drug that nearly doubles the life expectancy for adult cystic fibrosis patients.

CASGEVY is the first, and only, gene editing therapy approved for the treatment of transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD) in Europe - - Italy has the largest ...

Enlaza's War-Lock platform uses covalent-acting protein drugs with non-natural amino acids, enhancing therapeutic windows for safer, effective treatments. The partnership targets autoimmune diseases ...

Vertex Pharmaceuticals is offering Enlaza Therapeutics more than $2 billion in biobucks through a multitarget drug discovery deal aiming to create new T-cell engagers and small-format drug conjugates.

Disappointing trial results for VX-993 led to a sell-off of Vertex's stock recently. The company's financials remain strong, and sales were up 12% last quarter. Vertex has been broadening its pipeline ...